Back to Results

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Title Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Therapeutic Area Cancer
Principal Investigator Rachel Buchsbaum, MD
Min Age 18 Years
Gender Any
Contact Latoya Lashley
More Information


This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials.

Study Details

Inclusion Criteria

1. Patient must have measurable disease 2. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-2 OR patient must have Lansky performance status of >= 50% or Karnofsky performance status of >= 50% 3. Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider

Exclusion Criteria

Study Requirements

All participants in this registration study are required to have had a sample of their tumor tested by a ComboMATCH-designated laboratory and have results that show the participant is able to join the study. If the tumor has a genetic change or mutation that is targeted by one or more of the drugs used in this study, participants will be asked to participate in that treatment trial.